Takeda reveals PhII fail for rare genetic condition, looks to new product pipeline to bolster growth

Nicole DeFeudis

Editor

Takeda’s Phase II program in a rare hereditary disease called metachromatic leukodystrophy (MLD) is “likely to be discontinued” after failing its primary and secondary endpoints …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER

Takeda reveals PhII fail for rare genetic condition, looks to new product pipeline to bolster growth

Nicole DeFeudis

Editor

Sign up to read this article for free.

Global Head of Marketing

Bachem

Bubendorf, BL, Switzerland

CBER's deputy director departs as staff shakeup continues

Bluebird bio to sell to investment funds after struggling to make money from gene therapies

FDA approves first drug to treat ultra-rare lipid storage disease

Eli Lilly stockpiles $548M of oral weight loss drug ahead of launch

FDA says Ozempic, Wegovy shortage is over

Trusted protection: Why the current meningococcal vaccination schedule shouldn’t change without strong evidence

Take­da re­veals PhII fail for rare ge­net­ic con­di­tion, looks to new prod­uct pipeline to bol­ster growth

Editor

Sign up to read this article for free.

Bachem

Bubendorf, BL, Switzerland

Takeda reveals PhII fail for rare genetic condition, looks to new product pipeline to bolster growth